1887

Journal of General Virology header logo

Volume 81, Issue 11

Update on adenovirus and its vectors Free

Preview this article:
Preview Magnify

There is no abstract available.

  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-81-11-2573
2000-11-01
2024-04-27
Loading full text...

Full text loading...

/deliver/fulltext/jgv/81/11/0812573a.html?itemId=/content/journal/jgv/10.1099/0022-1317-81-11-2573&mimeType=html&fmt=ahah

References

  1. Acsadi G., O’Hagan D., Lochmuller H., Prescott S., Larochelle N., Nalbantoglu J., Jani A., Karpati G. 1998; Interferons impair early transgene expression by adenovirus-mediated gene transfer in muscle cells. Journal of Molecular Medicine 76:442–450
     [Google Scholar]
  2. Adachi Y., Tamiya T., Ichikawa T., Terada K., Ono Y., Matsumoto K., Furuta T., Hamada H., Ohmoto T. 2000; Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine. Human Gene Therapy 11:77–89
     [Google Scholar]
  3. Addison C. L., Bramson J. L., Hitt M. M., Muller W. J., Gauldie J., Graham F. L. 1998; Intratumoral coinjection of adenoviral vectors expressing IL-2 and IL-12 results in enhanced frequency of regression of injected and untreated distal tumors. Gene Therapy 5:1400–1409
     [Google Scholar]
  4. Alton E. W., Stern M., Farley R., Jaffe A., Chadwick S. L., Phillips J., Davies J., Smith S. N., Browning J., Davies M. G., Hodson M. E., Durham S. R., Li D., Jeffery P. K., Scallan M., Balfour R., Eastman S. J., Cheng S. H., Smith A. E., Meeker D., Geddes D. M. 1999; Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353:947–954
     [Google Scholar]
  5. Amalfitano A., Hauser M. A., Hu H., Serra D., Begy C. R., Chamberlain J. S. 1998; Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. Journal of Virology 72:926–933
     [Google Scholar]
  6. Amalfitano A., McVie-Wylie A. J., Hu H., Dawson T. L., Raben N., Plotz P., Chen Y. T. 1999; Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proceedings of the National Academy of Sciences USA: 96:8861–8866
     [Google Scholar]
  7. Anderson C. W., Young M. E., Flint S. J. 1989; Characterization of the adenovirus 2 virion protein, mu. Virology 172:506–512
     [Google Scholar]
  8. Anderson S. C., Johnson D. E., Harris M. P., Engler H., Hancock W., Huang W. M., Wills K. N., Gregory R. J., Sutjipto S., Wen S. F., Lofgren S., Shepard H. M., Maneval D. C. 1998; p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clinical Cancer Research 4:1649–1659
     [Google Scholar]
  9. Angeletti P. C., Engler J. A. 1998; Adenovirus preterminal protein binds to the CAD enzyme at active sites of viral DNA replication on the nuclear matrix. Journal of Virology 72:2896–2904
     [Google Scholar]
  10. Arany Z., Newsome D., Oldread E., Livingston D. M., Eckner R. 1995; A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 374:81–84
     [Google Scholar]
  11. Armentano D., Zabner J., Sacks C., Sookdeo C. C., Smith M. P., St George J. A., Wadsworth S. C., Smith A. E., Gregory R. J. 1997; Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. Journal of Virology 71:2408–2416
     [Google Scholar]
  12. Arnberg N., Edlund K., Kidd A. H., Wadell G. 2000; Adenovirus type 37 uses sialic acid as a cellular receptor. Journal of Virology 74:42–48
     [Google Scholar]
  13. Badrichani A. Z., Stroka D. M., Bilbao G., Curiel D. T., Bach F. H., Ferran C. 1999; Bcl-2 and Bcl-XL serve an anti-inflammatory function in endothelial cells through inhibition of NF-kappaB. Journal of Clinical Investigation 103:543–553
     [Google Scholar]
  14. Baker A., Saltik M., Lehrmann H., Killisch I., Mautner V., Lamm G., Christofori G., Cotten M. 1997; Polyethylenimine (PEI) is a simple, inexpensive and effective reagent for condensing and linking plasmid DNA to adenovirus for gene delivery. Gene Therapy 4:773–782
     [Google Scholar]
  15. Balachandran S., Roberts P. C., Kipperman T., Bhalla K. N., Compans R. W., Archer D. R., Barber G. N. 2000; Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. Journal of Virology 74:1513–1523
     [Google Scholar]
  16. Balagu C., Zhou J., Dai Y., Alemany R., Josephs S. F., Andreason G., Hariharan M., Sethi E., Prokopenko E., Jan H., Lou Y. C., Hubert-Leslie D., Ruiz L., Zhang W. W. 2000; Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 95:820–828
     [Google Scholar]
  17. Bals R., Weiner D. J., Moscioni A. D., Meegalla R. L., Wilson J. M. 1999; Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infection and Immunity 67:6084–6089
     [Google Scholar]
  18. Barkats M., Bilang-Bleuel A., Buc-Caron M. H., Castel-Barthe M. N., Corti O., Finiels F., Horellou P., Revah F., Sabate O., Mallet J. 1998; Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases. Progress in Neurobiology 55:333–341
     [Google Scholar]
  19. Bastian A., Bewig B. 1999; Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage fluid. Gene Therapy 6:637–642
     [Google Scholar]
  20. Batshaw M. L., Wilson J. M., Raper S., Yudkoff M., Robinson M. B. 1999; Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). Human Gene Therapy 10:2419–2437
     [Google Scholar]
  21. Bemelmans A. P., Horellou P., Pradier L., Brunet I., Colin P., Mallet J. 1999; Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington’s disease, as demonstrated by adenoviral gene transfer. Human Gene Therapy 10:2987–2997
     [Google Scholar]
  22. Benihoud K., Yeh P., Perricaudet M. 1999; Adenovirus vectors for gene delivery. Current Opinions in Biotechnology 10:440–447
     [Google Scholar]
  23. Benkő M., Harrach B., Russell W. C. 1999; Adenoviridae. In Virus Taxonomy. Seventh Report of the International Committee on Taxonomy of Viruses pp 227–238 Edited by van Regenmortel M. H. V., Fauquet C. M., Bishop D. H. L. San Diego: Academic Press;
     [Google Scholar]
  24. Bennett E. M., Bennink J. R., Yewdell J. W., Brodsky F. M. 1999; Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. Journal of Immunology 162:5049–5052
     [Google Scholar]
  25. Bergelson J. M., Cunningham J. A., Droguett G., Kurt-Jones E. A., Krithivas A., Hong J. S., Horwitz M. S., Crowell R. L., Finberg R. W. 1997; Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323
     [Google Scholar]
  26. Bewley M. C., Springer K., Zhang Y. B., Freimuth P., Flanagan J. M. 1999; Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 286:1579–1583
     [Google Scholar]
  27. Bilbao G., Contreras J. L., Gomez-Navarro J., Eckhoff D. E., Mikheeva G., Krasnykh V., Hynes T., Thomas F. T., Thomas J. M., Curiel D. T. 1999a; Genetic modification of liver grafts with an adenoviral vector encoding the Bcl-2 gene improves organ preservation. Transplantation 67:775–783
     [Google Scholar]
  28. Bilbao G., Contreras J. L., Zhang H. G., Pike M. J., Overturf K., Mikheeva G., Krasnykh V., Curiel D. T. 1999b; Adenovirus-mediated gene expression in vivo is enhanced by the antiapoptotic bcl-2 gene. Journal of Virology 73:6992–7000
     [Google Scholar]
  29. Bischof J., Vietor I., Cotten M., Huber L. A. 1999; Transient transfection of mammary epithelial cells with a PEI/DNA/adenovirus system. Biological Chemistry 380:269–273
     [Google Scholar]
  30. Bischoff J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A., McCormick F. 1996; An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373–376
     [Google Scholar]
  31. Blackburn R. V., Galoforo S. S., Corry P. M., Lee Y. J. 1999; Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity. International Journal of Cancer 82:293–297
     [Google Scholar]
  32. Blagosklonny M. V., Giannakakou P., Wojtowicz M., Romanova L. Y., Ain K. B., Bates S. E., Fojo T. 1998; Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. Journal of Endocrine Metabolism 83:2516–2522
     [Google Scholar]
  33. Boivin D., Morrison M. R., Marcellus R. C., Querido E., Branton P. E. 1999; Analysis of synthesis, stability, phosphorylation, and interacting polypeptides of the 34-kilodalton product of open reading frame 6 and of the early region 4 protein of human adenovirus type 5. Journal of Virology 73:1245–1253
     [Google Scholar]
  34. Bondeson J., Browne K. A., Brennan F. M., Foxwell B. M., Feldmann M. 1999a; Selective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-κB independent. Journal of Immunology 162:2939–2945
     [Google Scholar]
  35. Bondeson J., Foxwell B., Brennan F., Feldmann M. 1999b; Defining therapeutic targets by using adenovirus: blocking NF-κB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proceedings of the National Academy of Sciences, USA 96:5668–5673
     [Google Scholar]
  36. Bouri K., Feero W. G., Myerburg M. M., Wickham T. J., Kovesdi I., Hoffman E. P., Clemens P. R. 1999; Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Human Gene Therapy 10:1633–1640
     [Google Scholar]
  37. Boyer J. L., Ketner G. 2000; Genetic analysis of a potential zinc-binding domain of the adenovirus E4 34k protein. Journal of Biological Chemistry 275:14969–14978
     [Google Scholar]
  38. Boyer J., Rohleder K., Ketner G. 1999a; Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 263:307–312
     [Google Scholar]
  39. Boyer T. G., Martin M. E., Lees E., Ricciardi R. P., Berk A. J. 1999b; Mammalian Srb/mediator complex is targeted by adenovirus E1A protein. Nature 399:276–279
     [Google Scholar]
  40. Brader K. R., Wolf J. K., Hung M. C., Yu D., Crispens M. A., van Golen K. L., Price J. E. 1997; Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clinical Cancer Research 3:2017–2024
     [Google Scholar]
  41. Bramson J. L., Hitt M., Addison C. L., Muller W. J., Gauldie J., Graham F. L. 1996; Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Human Gene Therapy 7:1995–2002
     [Google Scholar]
  42. Brehm A., Miska E. A., McCance D. J., Reid J. L., Bannister A. J., Kouzarides T. 1998; Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597–601
     [Google Scholar]
  43. Bruce C. B., Akrigg A., Sharpe S. A., Hanke T., Wilkinson G. W. G., Cranage M. P. 1999; Replication-deficient recombinant adenoviruses expressing the human immunodeficiency virus Env antigen can induce both humoral and CTL immune responses in mice. Journal of General Virology 80:2621–2628
     [Google Scholar]
  44. Bruder J. T., Kovesdi I. 1997; Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. Journal of Virology 71:398–404
     [Google Scholar]
  45. Bruder J. T., Appiah A., Kirkman W. M.III., Chen P., Tian J., Reddy D., Brough D. E., Lizonova A., Kovesdi I. 2000; Improved production of adenovirus vectors expressing apoptotic transgenes. Human Gene Therapy 11:139–149
     [Google Scholar]
  46. Campain J. A., Matassa A. A., Felgner P. L., Barnhart K. M., Curiel D. T., Harrison G. S. 1998; Lipid- and adenoviral-mediated gene transfer into AIDS-Kaposi’s sarcoma cell lines. Cancer Gene Therapy 5:131–143
     [Google Scholar]
  47. Cao X., Ju D. W., Tao Q., Wang J., Wan T., Wang B. M., Zhang W., Hamada H. 1998; Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice. Gene Therapy 5:1130–1136
     [Google Scholar]
  48. Caplen N. J., Higginbotham J. N., Scheel J. R., Vahanian N., Yoshida Y., Hamada H., Blaese R. M., Ramsey W. J. 1999; Adeno-retroviral chimeric viruses as in vivo transducing agents. Gene Therapy 6:454–459
     [Google Scholar]
  49. Chakravarti D., Ogryzko V., Kao H. Y., Nash A., Chen H., Nakatani Y., Evans R. M. 1999; A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96:393–403
     [Google Scholar]
  50. Chanock R. M., Ludwig W., Heubner R. J., Cate T. R., Chu L. W. 1966; Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. Journal of the American Medical Association 195:445–452
     [Google Scholar]
  51. Charles P. C., Chen X., Horwitz M. S., Brosnan C. F. 1999; Differential chemokine induction by the mouse adenovirus type-1 in the central nervous system of susceptible and resistant strains of mice. Journal of Neurovirology 5:55–64
     [Google Scholar]
  52. Chen L., Anton M., Graham F. L. 1996; Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somatic Cell Molecular Genetics 22:477–488
     [Google Scholar]
  53. Chillon M., Bosch A., Zabner J., Law L., Armentano D., Welsh M. J., Davidson B. L. 1999; Group D adenoviruses infect primary central nervous system cells more efficiently than those from group C. Journal of Virology 73:2537–2540
     [Google Scholar]
  54. Chiou S. K., White E. 1998; Inhibition of ICE-like proteases inhibits apoptosis and increases virus production during adenovirus infection. Virology 244:108–118
     [Google Scholar]
  55. Chirmule N., Hughes J. V., Gao G. P., Raper S. E., Wilson J. M. 1998; Role of E4 in eliciting CD4 T-cell and B-cell responses to adenovirus vectors delivered to murine and nonhuman primate lungs. Journal of Virology 72:6138–6145
     [Google Scholar]
  56. Chirmule N., Moscioni A. D., Qian Y., Qian R., Chen Y., Wilson J. M. 1999; Fas–Fas ligand interactions play a major role in effector functions of cytotoxic T lymphocytes after adenovirus vector-mediated gene transfer. Human Gene Therapy 10:259–269
     [Google Scholar]
  57. Chiu C. Y., Mathias P., Nemerow G. R., Stewart P. L. 1999; Structure of adenovirus complexed with its internalization receptor, αvβ5 integrin. Journal of Virology 73:6759–6768
     [Google Scholar]
  58. Chroboczek J., Ruigrok R. W. H., Cusack S. 1995; Adenovirus fiber. In The Molecular Repertoire of Adenoviruses pp 163–200 Edited by Doerfler W., Bohm P. Berlin: Springer;
     [Google Scholar]
  59. Cirielli C., Inyaku K., Capogrossi M. C., Yuan X., Williams J. A. 1999; Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma. Journal of Neuroncology 43:99–108
     [Google Scholar]
  60. Clesham G. J., Adam P. J., Proudfoot D., Flynn P. D., Efstathiou S., Weissberg P. L. 1998; High adenoviral loads stimulate NF kappaB-dependent gene expression in human vascular smooth muscle cells. Gene Therapy 5:174–180
     [Google Scholar]
  61. Cook J. L., Routes B. A., Walker T. A., Colvin K. L., Routes J. M. 1999; E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target cell sensitization to apoptotic injury. Experimental Cell Research 251:414–423
     [Google Scholar]
  62. Corti O., Sabate O., Horellou P., Colin P., Dumas S., Buchet D., Buc-Caron M. H., Mallet J. 1999a; A single adenovirus vector mediates doxycycline-controlled expression of tyrosine hydroxylase in brain grafts of human neural progenitors. Nature Biotechnology 17:349–354
     [Google Scholar]
  63. Corti O., Sanchez-Capelo A., Colin P., Hanoun N., Hamon M., Mallet J. 1999b; Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson’s disease. Proceedings of the National Academy of Sciences, USA 96:12120–12125
     [Google Scholar]
  64. Croyle M. A., Roessler B. J., Hsu C. P., Sun R., Amidon G. L. 1998a; Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharmacy Research 15:1348–1355
     [Google Scholar]
  65. Croyle M. A., Stone M., Amidon G. L., Roessler B. J. 1998b; In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine. Gene Therapy 5:645–654
     [Google Scholar]
  66. Croyle M. A., Walter E., Janich S., Roessler B. J., Amidon G. L. 1998c; Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium. Human Gene Therapy 9:561–573
     [Google Scholar]
  67. Crystal R. G. 1999; In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors. Cancer Chemotherapy and Pharmacology 43:S90–S99
     [Google Scholar]
  68. Dales S., Chardonnet Y. 1973; Early events in the interaction of adenoviruses with HeLa cells. IV. Association with microtubules and the nuclear pore complex during vectorial movement of the inoculum. Virology 56:465–483
     [Google Scholar]
  69. De Geest B., Van Linthout S., Lox M., Collen D., Holvoet P. 2000; Sustained expression of human apolipoprotein A-I after adenoviral gene transfer in C57BL/6 mice: role of apolipoprotein A-I promoter, apolipoprotein A-I introns, and human apolipoprotein E enhancer. Human Gene Therapy 11:101–112
     [Google Scholar]
  70. de Moissac D., Zheng H., Kirshenbaum L. A. 1999; Linkage of the BH4 domain of Bcl-2 and the nuclear factor kappaB signaling pathway for suppression of apoptosis. Journal of Biological Chemistry 274:29505–29509
     [Google Scholar]
  71. Deryckere F., Burgert H. G. 1996; Tumor necrosis factor alpha induces the adenovirus early 3 promoter by activation of NF-kappaB. Journal of Biological Chemistry 271:30249–30255
     [Google Scholar]
  72. de Stanchina E., McCurrach M. E., Zindy F., Shieh S. Y., Ferbeyre G., Samuelson A. V., Prives C., Roussel M. F., Sherr C. J., Lowe S. W. 1998; E1A signaling to p53 involves the p19 (ARF) tumor suppressor. Genes & Development 12:2434–2442
     [Google Scholar]
  73. Desterro J. M., Rodriguez M. S., Kemp G. D., Hay R. T. 1999; Identification of the enzyme required for activation of the small ubiquitin-like protein SUMO-1. Journal of Biological Chemistry 274:10618–10624
     [Google Scholar]
  74. Dewey R. A., Morrissey G., Cowsill C. M., Stone D., Bolognani F., Dodd N. J., Southgate T. D., Klatzmann D., Lassmann H., Castro M. G., Lowenstein P. R. 1999; Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nature Medicine 5:1256–1263
     [Google Scholar]
  75. Diaz R. M., Todryk S., Chong H., Hart I. R., Sikora K., Dorudi S., Vile R. G. 1998; Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Therapy 5:869–879
     [Google Scholar]
  76. Dodds E., Piper T. A., Murphy S. J., Dickson G. 1999; Cationic lipids and polymers are able to enhance adenoviral infection of cultured mouse myotubes. Journal of Neurochemistry 72:2105–2112
     [Google Scholar]
  77. Dorai T., Perlman H., Walsh K., Shabsigh A., Goluboff E. T., Olsson C. A., Buttyan R. 1999; A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. International Journal of Cancer 82:846–852
     [Google Scholar]
  78. Dorsman J. C., Teunisse A. F. A. S., Zantema A., van der Eb A. J. 1997; The adenovirus 12 E1A proteins can bind directly to proteins of the p300 transcription co-activator family, including the CREB-binding protein CBP and p300. Journal of General Virology 78:423–426
     [Google Scholar]
  79. Doucas V., Ishov A. M., Romo A., Juguilon H., Weitzman M. D., Evans R. M., Maul G. G. 1996; Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes & Development 10:196–207
     [Google Scholar]
  80. Douglas J. T., Miller C. R., Kim M., Dmitriev I., Mikheeva G., Krasnykh V., Curiel D. T. 1999; A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nature Biotechnology 17:470–475
     [Google Scholar]
  81. Dunphy E. J., Redman R. A., Herweijer H., Cripe T. P. 1999; Reciprocal enhancement of gene transfer by combinatorial adenovirus transduction and plasmid DNA transfection in vitro and in vivo. Human Gene Therapy 10:2407–2417
     [Google Scholar]
  82. Edgell C. J., Curiel D. T., Hu P. C., Marr H. S. 1998; Efficient gene transfer to human endothelial cells using DNA complexed to adenovirus particles. Biotechniques 25:264–268, 270–272
     [Google Scholar]
  83. Einfeld D. A., Brough D. E., Roelvink P. W., Kovesdi I., Wickham T. J. 1999; Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. Journal of Virology 73:9130–9136
     [Google Scholar]
  84. Eischen C. M., Weber J. D., Roussel M. F., Sherr C. J., Cleveland J. L. 1999; Disruption of the ARF–Mdm2–p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes & Development 13:2658–2669
     [Google Scholar]
  85. Eissa N. T., Chu C. S., Danel C., Crystal R. G. 1994; Evaluation of the respiratory epithelium of normals and individuals with cystic fibrosis for the presence of adenovirus E1a sequences relevant to the use of E1a− adenovirus vectors for gene therapy for the respiratory manifestations of cystic fibrosis. Human Gene Therapy 5:1105–1114
     [Google Scholar]
  86. Elkon K. B., Liu C. C., Gall J. G., Trevejo J., Marino M. W., Abrahamsen K. A., Song X., Zhou J. L., Old J. L., Crystal R. G., Falck-Pederson E. 1997; Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors. Proceedings of the National Academy of Sciences, USA 94:9814–9819
     [Google Scholar]
  87. Elliott W. M., Hayashi S., Hogg J. C. 1995; Immunodetection of adenoviral E1A proteins in human lung tissue. American Journal of Respiratory Cell Molecular Biology 12:642–648
     [Google Scholar]
  88. Emtage P. C., Wan Y., Hitt M., Graham F. L., Muller W. J., Zlotnik A., Gauldie J. 1999; Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Human Gene Therapy 10:697–709
     [Google Scholar]
  89. Faha B., Harlow E., Lees E. 1993; The adenovirus E1A-associated kinase consists of cyclin E–p33cdk2 and cyclin A–p33cdk2. Journal of Virology 67:2456–2465
     [Google Scholar]
  90. Fallaux F. J., Bout A., van der Velde I., van der Wollenberg D. J., Hehir K. M., Keegan J., Augur C., Cramer S. J., van Ormondt H., van der Eb A. J., Valerio D., Hoeben R. C. 1998; New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human Gene Therapy 9:1909–1917
     [Google Scholar]
  91. Fallaux F. J., van der Eb A. J., Hoeben R. C. 1999; Who’s afraid of replication-competent adenoviruses?Gene Therapy. 6709–712
  92. Fasbender A., Zabner J., Chillon M., Moninger T. O., Puga A. P., Davidson B. L., Welsh M. J. 1997; Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. Journal of Biological Chemistry 272:6479–6489
     [Google Scholar]
  93. Fasbender A., Lee J. H., Walters R. W., Moninger T. O., Zabner J., Welsh M. J. 1998; Incorporation of adenovirus in calcium phosphate precipitates enhances gene transfer to airway epithelia in vitro and in vivo. Journal of Clinical Investigation 102:184–193
     [Google Scholar]
  94. Fechner H., Haack A., Wang H., Wang X., Eizema K., Pauschinger M., Schoemaker R., Veghel R., Houtsmuller A., Schultheiss H. P., Lamers J., Poller W. 1999; Expression of coxsackie adenovirus receptor and αv-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Therapy 6:1520–1535
     [Google Scholar]
  95. Feigenblum D., Walker R., Schneider R. J. 1998; Adenovirus induction of an interferon-regulatory factor during entry into the late phase of infection. Journal of Virology 72:9257–9266
     [Google Scholar]
  96. Ferreira V., Sidenius N., Tarantino N., Hubert P., Chatenoud L., Blasi F., Korner M. 1999; In vivo inhibition of NF-kappa B in T-lineage cells leads to a dramatic decrease in cell proliferation and cytokine production and to increased cell apoptosis in response to mitogenic stimuli, but not to abnormal thymopoiesis. Journal of Immunology 162:6442–6450
     [Google Scholar]
  97. Fessler S. P., Young C. S. 1998; Control of adenovirus early gene expression during the late phase of infection. Journal of Virology 72:4049–4056
     [Google Scholar]
  98. Fisher L. J. 1997; Neural precursor cells: applications for the study and repair of the central nervous system. Neurobiology and Disease 4:1–22
     [Google Scholar]
  99. Fisher K., Stallwood Y., Ulbrich K., Mautner V., Seymour L. 2000; Protection and retargeting of adenovirus using a multifunctional hydrophilic polymer. Molecular Therapy 1:S57
     [Google Scholar]
  100. Flomenberg P., Piaskowski V., Truitt R. L., Casper J. T. 1995; Characterization of human proliferative T cell responses to adenoviruses. Journal of Infectious Diseases 171:1090–1096
     [Google Scholar]
  101. Foxwell B., Browne K., Bondeson J., Clarke C., de Martin R., Brennan F., Feldmann M. 1998; Efficient adenoviral infection with IκB α reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proceedings of the National Academy of Sciences, USA 95:8211–8215
     [Google Scholar]
  102. Franklin C. M. 1999; Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. Seminars on Arthritis and Rheumatism 29:172–181
     [Google Scholar]
  103. Fredman J. N., Engler J. A. 1993; Adenovirus precursor to terminal protein interacts with the nuclear matrix in vivo and in vitro. Journal of Virology 67:3384–3395
     [Google Scholar]
  104. Fujii T., Garcia-Bermejo M. L., Bernabo J. L., Caamano J., Ohba M., Kuroki T., Li L., Yuspa S. H., Kazanietz M. G. 2000; Involvement of protein kinase C δ (PKCδ) in phorbol ester-induced apoptosis in LNCaP prostate cancer cells. Lack of proteolytic cleavage of PKCδ. Journal of Biological Chemistry 275:7574–7582
     [Google Scholar]
  105. Gabaglia C. R., Pedersen B., Hitt M., Burdin N., Sercarz E. E., Graham F. L., Gauldie J., Braciak T. A. 1999; A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice. Journal of Immunology 162:753–760
     [Google Scholar]
  106. Gahery-Segard H., Juillard V., Gaston J., Lengagne R., Pavirani A., Boulanger P., Guillet J. G. 1997; Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus-induced Ig subclass shifts. European Journal of Immunology 27:653–659
     [Google Scholar]
  107. Gahery-Segard H., Farace F., Godfrin D., Gaston J., Lengagne R., Tursz T., Boulanger P., Guillet J. G. 1998; Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. Journal of Virology 72:2388–2397
     [Google Scholar]
  108. Gambotto A., Tuting T., McVey D. L., Kovesdi I., Tahara H., Lotze M. T., Robbins P. D. 1999; Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12. Cancer Gene Therapy 6:45–53
     [Google Scholar]
  109. Ganz T., Lehrer R. I. 1998; Antimicrobial peptides of vertebrates. Current Opinions in Immunology 10:41–44
     [Google Scholar]
  110. Gao G. P., Engdahl R. K., Wilson J. M. 2000; A cell line for high-yield production of E1-deleted adenovirus vectors without the emergence of replication-competent virus. Human Gene Therapy 11:213–219
     [Google Scholar]
  111. Ghivizzani S. C., Lechman E. R., Kang R., Tio C., Kolls J., Evans C. H., Robbins P. D. 1998; Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proceedings of the National Academy of Sciences, USA 95:4613–4618
     [Google Scholar]
  112. Ghoda L., Lin X., Greene W. C. 1997; The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IκBα and stimulates its degradation in vitro. Journal of Biological Chemistry 272:21281–21288
     [Google Scholar]
  113. Gilbert R., Nalbantoglu J., Petrof B. J., Ebihara S., Guibinga G. H., Tinsley J. M., Kamen A., Massie B., Davies K. E., Karpati G. 1999; Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Human Gene Therapy 10:1299–1310
     [Google Scholar]
  114. Ginsberg H. S., Moldawer L. L., Prince G. A. 1999; Role of the type 5 adenovirus gene encoding the early region 1B 55-kDa protein in pulmonary pathogenesis. Proceedings of the National Academy of Sciences, USA 96:10409–10411
     [Google Scholar]
  115. Goebel E. A., Davidson B. L., Graham S. M., Kern J. A. 1998; Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma. Otolaryngology and Head and Neck Surgery 119:331–336
     [Google Scholar]
  116. Goodbourn S., Didcock L., Randall R. E. 2000; Interferons: cell signalling, immune modulation, antiviral responses and virus countermeasures. Journal of General Virology 81:2341–2365
     [Google Scholar]
  117. Goodrum F. D., Ornelles D. A. 1999; Roles for the E4 orf6, orf3, and E1B 55-kilodalton proteins in cell cycle-independent adenovirus replication. Journal of Virology 73:7474–7488
     [Google Scholar]
  118. Gorziglia M. I., Lapcevich C., Roy S., Kang Q., Kadan M., Wu V., Pechan P., Kaleko M. 1999; Generation of an adenovirus vector lacking E1, E2a, E3, and all of E4 except open reading frame 3. Journal of Virology 73:6048–6055
     [Google Scholar]
  119. Graham F. L., Prevec L. 1992; Adenovirus-based expression vectors and recombinant vaccines. Biotechnology 20:363–390
     [Google Scholar]
  120. Graham F. L., Smiley J., Russell W. C., Nairn R. 1977; Characteristics of a human cell line transformed by DNA from human adenovirus type 5. Journal of General Virology 36:59–72
     [Google Scholar]
  121. Grand R. J., Turnell A. S., Mason G. G., Wang W., Milner A. E., Mymryk J. S., Rookes S. M., Rivett A. J., Gallimore P. H. 1999a; Adenovirus early region 1A protein binds to mammalian SUG1 – a regulatory component of the proteasome. Oncogene 18:449–458
     [Google Scholar]
  122. Grand R. J., Parkhill J., Szestak T., Rookes S. M., Roberts S., Gallimore P. H. 1999b; Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein. Oncogene 18:955–965
     [Google Scholar]
  123. Greber U. F., Webster P., Weber J., Helenius A. 1996; The role of the adenovirus protease on virus entry into cells. EMBO Journal 15:1766–1777
     [Google Scholar]
  124. Greber U. F., Suomalainen M., Stidwill R. P., Boucke K., Ebersold M. W., Helenius A. 1997; The role of the nuclear pore complex in adenovirus DNA entry. EMBO Journal 16:5998–6007
     [Google Scholar]
  125. Gropp R., Frye M., Wagner T. O., Bargon J. 1999; Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. Gene Therapy 10:957–964
     [Google Scholar]
  126. Guidotti J. E., Mignon A., Haase G., Caillaud C., McDonell N., Kahn A., Poenaru L. 1999; Adenoviral gene therapy of the Tay–Sachs disease in hexosaminidase A-deficient knock-out mice. Human Molecular Genetics 8:831–838
     [Google Scholar]
  127. Haase G., Pettmann B., Bordet T., Villa P., Vigne E., Schmalbruch H., Kahn A. 1999; Therapeutic benefit of ciliary neurotrophic factor in progressive motor neuronopathy depends on the route of delivery. Annals of Neurology 45:296–304
     [Google Scholar]
  128. Halbert D. N., Cutt J. R., Shenk T. 1985; Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. Journal of Virology 56:250–257
     [Google Scholar]
  129. Hale T. K., Braithwaite A. W. 1999; The adenovirus oncoprotein E1a stimulates binding of transcription factor ETF to transcriptionally activate the p53 gene. Journal of Biological Chemistry 274:23777–23786
     [Google Scholar]
  130. Hall A. R., Dix B. R., O’Carroll S. J., Braithwaite A. W. 1998; p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nature Medicine 4:1068–1072
     [Google Scholar]
  131. Hamamori Y., Sartorelli V., Ogryzko V., Puri P. L., Wu H. Y., Wang J. Y., Nakatani Y., Kedes L. 1999; Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A. Cell 96:405–413
     [Google Scholar]
  132. Hammond J. M., McCoy R. J., Jansen E. S., Morrissy C. J., Hodgson A. L., Johnson M. A. 2000; Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 18:1040–1050
     [Google Scholar]
  133. Han J., Sabbatini P., Perez D., Rao L., Modha D., White E. 1996; The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes & Development 10:461–477
     [Google Scholar]
  134. Harada J. N., Berk A. J. 1999; p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. Journal of Virology 73:5333–5344
     [Google Scholar]
  135. Harari O. A., Wickham T. J., Stocker C. J., Kovesdi I., Segal D. M., Huehns T. Y., Sarraf C., Haskard D. O. 1999; Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Therapy 6:801–807
     [Google Scholar]
  136. Hardy S., Kitamura M., Harris-Stansil T., Dai Y., Phipps M. L. 1997; Construction of adenovirus vectors through Cre-lox recombination. Journal of Virology 71:1842–1849
     [Google Scholar]
  137. Harrod K. S., Hermiston T. W., Trapnell B. C., Wold W. S., Whitsett J. A. 1998; Lung-specific expression of adenovirus E3-14.7K in transgenic mice attenuates adenoviral vector-mediated lung inflammation and enhances transgene expression. Human Gene Therapy 9:1885–1898
     [Google Scholar]
  138. Hart I. R. 1996; Transcriptionally targeted gene therapy. Current Topics in Microbiology and Immunology 213:19–25
     [Google Scholar]
  139. Hartigan-O’Connor D., Amalfitano A., Chamberlain J. S. 1999; Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. Journal of Virology 73:7835–7841
     [Google Scholar]
  140. Harvey B. G., Hackett N. R., El-Sawy T., Rosengart T. K., Hirschowitz E. A., Lieberman M. D., Lesser M. L., Crystal R. G. 1999; Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. Journal of Virology 73:6729–6742
     [Google Scholar]
  141. Hateboer G., Hijmans E. M., Nooij J. B., Schlenker S., Jentsch S., Bernards R. 1996; mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect. Journal of Biological Chemistry 271:25906–25911
     [Google Scholar]
  142. Hautala T., Grunst T., Fabrega A., Freimuth P., Welsh M. J. 1998; An interaction between penton base and alpha v integrins plays a minimal role in adenovirus-mediated gene transfer to hepatocytes in vitro and in vivo. Gene Therapy 5:1259–1264
     [Google Scholar]
  143. Hay R. T., Freeman A., Leith I., Monaghan A., Webster A. 1995; Molecular interactions during adenovirus DNA replication. In The Molecular Repertoire of Adenoviruses pp 31–48 Edited by Doerfler W., Bohm P. Berlin: Springer;
     [Google Scholar]
  144. Hay J. G., Shapiro N., Sauthoff H., Heitner S., Phupakdi W., Rom W. N. 1999a; Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. Human Gene Therapy 10:579–590
     [Google Scholar]
  145. Hay R. T., Vuillard L., Desterro J. M., Rodriguez M. S. 1999b; Control of NF-κB transcriptional activation by signal induced proteolysis of IκB α. Philosophical Transactions of the Royal Society Series B 354:1601–1609
     [Google Scholar]
  146. Hayes A. L., Smith C., Foxwell B. M., Brennan F. M. 1999; CD45-induced tumor necrosis factor alpha production in monocytes is phosphatidylinositol 3-kinase-dependent and nuclear factor-kappaB-independent. Journal of Biological Chemistry 274:33455–33461
     [Google Scholar]
  147. He T. C., Zhou S., da Costa L. T., Yu J., Kinzler K. W., Vogelstein B. 1998; A simplified system for generating recombinant adenoviruses. Proceedings of the National Academy of Sciences, USA 95:2509–2514
     [Google Scholar]
  148. He Z., Wlazlo A. P., Kowalczyk D. W., Cheng J., Xiang Z. Q., Giles-Davis W., Ertl H. C. 2000; Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270:146–161
     [Google Scholar]
  149. Hearing P., Samulski R. J., Wishart W. L., Shenk T. 1987; Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. Journal of Virology 61:2555–2558
     [Google Scholar]
  150. Hedlund T. E., Meech S. J., Srikanth S., Kraft A. S., Miller G. J., Schaack J. B., Duke R. C. 1999; Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death and Differentiation 6:175–182
     [Google Scholar]
  151. Hehir K. M., Armentano D., Cardoza L. M., Choquette T. L., Berthelette P. B., White G. A., Couture L. A., Everton M. B., Keegan J., Martin J. M., Pratt D. A., Smith M. P., Smith A. E., Wadsworth S. C. 1996; Molecular characterization of replication-competent variants of adenovirus vectors and genome modifications to prevent their occurrence. Journal of Virology 70:8459–8467
     [Google Scholar]
  152. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D. D., Kirn D. H. 1997; ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Medicine 3:639–645
     [Google Scholar]
  153. Heise C. C., Williams A. M., Xue S., Propst M., Kirn D. H. 1999; Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Research 59:2623–2628
     [Google Scholar]
  154. Herman J. R., Adler H. L., Aguilar-Cordova E., Rojas-Martinez A., Woo S., Timme T. L., Wheeler T. M., Thompson T. C., Scardino P. T. 1999; In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Human Gene Therapy 10:1239–1249
     [Google Scholar]
  155. Hidaka C., Milano E., Leopold P. L., Bergelson J. M., Hackett N. R., Finberg R. W., Wickham T. J., Kovesdi I., Roelvink P., Crystal R. G. 1999; CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. Journal of Clinical Investigation 103:579–587
     [Google Scholar]
  156. Hillemann M. R., Werner J. R. 1954; Recovery of a new agent from patients with acute respiratory illness. Proceedings of the Society for Experimental Biology and Medicine 85:183–188
     [Google Scholar]
  157. Hirschowitz E. A., Crystal R. G. 1999; Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases. American Journal of Respiratory Cell and Molecular Biology 20:935–941
     [Google Scholar]
  158. Hirschowitz E. A., Ohwada A., Pascal W. R., Russi T. J., Crystal R. G. 1995; In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Human Gene Therapy 6:1055–1063
     [Google Scholar]
  159. Hitt M. M., Addison C. L., Graham F. L. 1997; Human adenovirus vectors for gene transfer into mammalian cells. Advances in Pharmacology 40:137–206
     [Google Scholar]
  160. Hofmann C., Loser P., Cichon G., Arnold W., Both G. W., Strauss M. 1999; Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo. Journal of Virology 73:6930–6936
     [Google Scholar]
  161. Honda R., Yasuda H. 1999; Association of p19 (ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO Journal 18:22–27
     [Google Scholar]
  162. Hong S. S., Karayan L., Tournier J., Curiel D. T., Boulanger P. A. 1997; Adenovirus type 5 fiber knob binds to MHC class I α2 domain at the surface of human epithelial and B lymphoblastoid cells. EMBO Journal 16:2294–2306
     [Google Scholar]
  163. Hong S. S., Galaup A., Peytavi R., Chazal N., Boulanger P. 1999a; Enhancement of adenovirus-mediated gene delivery by use of an oligopeptide with dual binding specificity. Human Gene Therapy 10:2577–2586
     [Google Scholar]
  164. Hong S. S., Gay B., Karayan L., Dabauvalle M. C., Boulanger P. 1999b; Cellular uptake and nuclear delivery of recombinant adenovirus penton base. Virology 262:163–177
     [Google Scholar]
  165. Horridge J. J., Leppard K. N. 1998; RNA-binding activity of the E1B 55-kilodalton protein from human adenovirus type 5. Journal of Virology 72:9374–9379
     [Google Scholar]
  166. Horwitz M. S., Evans C. F., McGavern D. B., Rodriguez M., Oldstone M. B. 1997; Primary demyelination in transgenic mice expressing interferon-gamma. Nature Medicine 3:1037–1041
     [Google Scholar]
  167. Howell J. M., Lochmuller H., O’Hara A., Fletcher S., Kakulas B. A., Massie B., Nalbantoglu J., Karpati G. 1998; High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Human Gene Therapy 9:629–634
     [Google Scholar]
  168. Huang S., Kamata T., Takada Y., Ruggeri Z. M., Nemerow G. R. 1996; Adenovirus interaction with distinct integrins mediates separate events in cell entry and gene delivery to hematopoietic cells. Journal of Virology 70:4502–4508
     [Google Scholar]
  169. Ilan Y., Attavar P., Takahashi M., Davidson A., Horwitz M. S., Guida J., Roy Chowdhury N., Roy Chowdhury J. 1996; Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. Journal of Clinical Investigation 98:2640–2647
     [Google Scholar]
  170. Ilan Y., Jona V. K., Sengupta K., Davidson A., Horwitz M. S., Roy-Chowdhury N., Roy-Chowdhury J. 1997; Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 26:949–956
     [Google Scholar]
  171. Ilan Y., Sauter B., Roy Chowdhury N., Reddy B. V. N., Thummala N. R., Droguett G., Davidson A., Ott M., Horwitz M. S., Roy Chowdhury J. 1998; Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 27:1368–1376
     [Google Scholar]
  172. Imazu T., Shimizu S., Tagami S., Matsushima M., Nakamura Y., Miki T., Okuyama A., Tsujimoto Y. 1999; Bcl-2/E1B 19 kDa-interacting protein 3-like protein (Bnip3L) interacts with bcl-2/Bcl-xL and induces apoptosis by altering mitochondrial membrane permeability. Oncogene 18:4523–4529
     [Google Scholar]
  173. Irie A., Anderegg B., Kashani-Sabet M., Ohkawa T., Suzuki T., Halks-Miller M., Curiel D. T., Scanlon K. J. 1999; Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. Antisense & Nucleic Acid Drug Development 9:341–349
     [Google Scholar]
  174. Iwamoto H. S., Trapnell B. C., McConnell C. J., Daugherty C., Whitsett J. A. 1999; Pulmonary inflammation associated with repeated, prenatal exposure to an E1, E3-deleted adenoviral vector in sheep. Gene Therapy 6:98–106
     [Google Scholar]
  175. Ji L., Bouvet M., Price R. E., Roth J. A., Fang B. 1999; Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1–E3 and inactivated E4 by GAL4–TATA replacement. Gene Therapy 6:393–442
     [Google Scholar]
  176. Jones N. 1995; Transcriptional modulation by the adenovirus E1A gene. Current Topics in Microbiology and Immunology 199:59–80
     [Google Scholar]
  177. Jooss K., Ertl H. C., Wilson J. M. 1998a; Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. Journal of Virology 72:2945–2954
     [Google Scholar]
  178. Jooss K., Turka L. A., Wilson J. M. 1998b; Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA4Ig. Gene Therapy 5:309–319
     [Google Scholar]
  179. Jooss K., Yang Y., Fisher K. J., Wilson J. M. 1998c; Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. Journal of Virology 72:4212–4223
     [Google Scholar]
  180. Ju D. W., Tao Q., Cheng D. S., Zhang W., Zhang M., Hamada H., Cao X. 2000; Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma. Gene Therapy 7:329–338
     [Google Scholar]
  181. Juillard V., Villefroy P., Godfrin D., Pavirani A., Venet A., Guillet J. G. 1995; Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. European Journal of Immunology 25:3467–3473
     [Google Scholar]
  182. Kaneko S., Hallenbeck P., Kotani T., Nakabayashi H., McGarrity G., Tamaoki T., Anderson W. F., Chiang Y. L. 1995; Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Research 55:5283–5287
     [Google Scholar]
  183. Kaner R. J., Worgall S., Leopold P. L., Stolze E., Milano E., Hidaka C., Ramalingam R., Hackett N. R., Singh R., Bergelson J., Finberg R., Falck-Pedersen E., Crystal R. G. 1999; Modification of the genetic program of human alveolar macrophages by adenovirus vectors in vitro is feasible but inefficient, limited in part by the low level of expression of the coxsackie/adenovirus receptor. American Journal of Respiratory Cell and Molecular Biology 20:361–370
     [Google Scholar]
  184. Kannabiran C., Morris G. F., Mathews M. B. 1999; Dual action of the adenovirus E1A 243R oncoprotein on the human proliferating cell nuclear antigen promoter: repression of transcriptional activation by p53. Oncogene 18:7825–7833
     [Google Scholar]
  185. Kaplan J. M., Smith A. E. 1997; Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Human Gene Therapy 8:1095–1104
     [Google Scholar]
  186. Kaplan J. M., Armentano D., Sparer T. E., Wynn S. G., Peterson P. A., Wadsworth S. C., Couture K. K., Pennington S. E., St George J. A., Gooding L. R., Smith A. E. 1997; Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Human Gene Therapy 8:45–56
     [Google Scholar]
  187. Kaplan J. M., Armentano D., Scaria A., Woodworth L. A., Pennington S. E., Wadsworth S. C., Smith A. E., Gregory R. J. 1999; Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes. Journal of Virology 73:4489–4492
     [Google Scholar]
  188. Kasof G. M., Goyal L., White E. 1999; Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. Molecular and Cell Biology 19:4390–4404
     [Google Scholar]
  189. Kass-Eisler A., Falck-Pedersen E., Elfenbein D. H., Alvira M., Buttrick P. M., Leinwand L. A. 1994; The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1:395–402
     [Google Scholar]
  190. Keblusek P., Dorsman J. C., Teunisse A. F. A. S., Teunissen H., van der Eb A. J., Zantema A. 1999; The adenoviral E1A oncoproteins interfere with the growth-inhibiting effect of the cdk-inhibitor p21CIP1/WAF1. Journal of General Virology 80:381–390
     [Google Scholar]
  191. Keicho N., Higashimoto Y., Bondy G. P., Elliott W. M., Hogg J. C., Hayashi S. 1999; Endotoxin-specific NF-kappaB activation in pulmonary epithelial cells harboring adenovirus E1A. American Journal of Physiology 277:L523–L532
     [Google Scholar]
  192. Kijima T., Osaki T., Nishino K., Kumagai T., Funakoshi T., Goto H., Tachibana I., Tanio Y., Kishimoto T. 1999; Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Research 59:4906–4911
     [Google Scholar]
  193. Kikuchi T., Crystal R. G. 1999; Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Human Gene Therapy 10:1375–1387
     [Google Scholar]
  194. Kim K. N., Watanabe S., Ma Y., Thornton S., Giannini E. H., Hirsch R. 2000; Viral IL-10 and soluble TNF receptor act synergistically to inhibit collagen-induced arthritis following adenovirus-mediated gene transfer. Journal of Immunology 164:1576–1581
     [Google Scholar]
  195. Kimura K., Gelmann E. P. 2000; Tumor necrosis factor-alpha and fas activate complementary fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. Journal of Biological Chemistry 275:8610–8617
     [Google Scholar]
  196. Kirby I., Davison E., Beavil A. J., Soh C. P., Wickham T. J., Roelvink P. W., Kovesdi I., Sutton B. J., Santis G. 1999; Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR. Journal of Virology 73:9508–9514
     [Google Scholar]
  197. Kirby I., Davison E., Beavil A. J., Soh C. P., Wickham T. J., Roelvink P. W., Kovesdi I., Sutton B. J., Santis G. 2000; Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein. Journal of Virology 74:2804–2813
     [Google Scholar]
  198. Konig C., Roth J., Dobbelstein M. 1999; Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55-kilodalton protein. Journal of Virology 73:2253–2262
     [Google Scholar]
  199. Krajcsi P., Dimitrov T., Hermiston T. W., Tollefson A. E., Ranheim T. S., Vande Pol S. B., Stephenson A. H., Wold W. S. 1996; The adenovirus E3-14.7K protein and the E3-10.4K/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. Journal of Virology 70:4904–4913
     [Google Scholar]
  200. Krasnykh V., Dmitriev I., Mikheeva G., Miller C. R., Belousova N., Curiel D. T. 1998; Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. Journal of Virology 72:1844–1852
     [Google Scholar]
  201. Kremer E. J., Boutin S., Chillon M., Danos O. 2000; Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. Journal of Virology 74:505–512
     [Google Scholar]
  202. Kuhnel F., Zender L., Paul Y., Tietze M. K., Trautwein C., Manns M., Kubicka S. 2000; NFκB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. Journal of Biological Chemistry 275:6421–6427
     [Google Scholar]
  203. Kumar-Singh R., Chamberlain J. S. 1996; Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Human Molecular Genetics 5:913–921
     [Google Scholar]
  204. Kvist S., Ostberg L., Persson H., Philipson L., Peterson P. A. 1978; Molecular association between transplantation antigens and cell surface antigen in adenovirus-transformed cell line. Proceedings of the National Academy of Sciences, USA 75:5674–5678
     [Google Scholar]
  205. Ladiwala U., Li H., Antel J. P., Nalbantoglu J. 1999; p53 induction by tumor necrosis factor-alpha and involvement of p53 in cell death of human oligodendrocytes. Journal of Neurochemistry 73:605–611
     [Google Scholar]
  206. Lanuti M., Gao G. P., Force S. D., Chang M. Y., El Kouri C., Amin K. M., Hughes J. V., Wilson J. M., Kaiser L. R., Albelda S. M. 1999; Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Human Gene Therapy 10:463–475
     [Google Scholar]
  207. Lechman E. R., Jaffurs D., Ghivizzani S. C., Gambotto A., Kovesdi I., Mi Z., Evans C. H., Robbins P. D. 1999; Direct adenoviral gene transfer of viral IL-10 to rabbit knees with experimental arthritis ameliorates disease in both injected and contralateral control knees. Journal of Immunology 163:2202–2208
     [Google Scholar]
  208. Lee J. H., Zabner J., Welsh M. J. 1999a; Delivery of an adenovirus vector in a calcium phosphate coprecipitate enhances the therapeutic index of gene transfer to airway epithelia. Human Gene Therapy 10:603–613
     [Google Scholar]
  209. Lee W. C., Wan Y. H., Li W., Fu F., Sime P. J., Gauldie J., Thomson A. W., Fung J. J., Lu L., Qian S. 1999b; Enhancement of dendritic cell tolerogenicity by genetic modification using adenoviral vectors encoding cDNA for TGF beta 1. Transplantation Proceedings 31:1195
     [Google Scholar]
  210. Legrand V., Spehner D., Schlesinger Y., Settelen N., Pavirani A., Mehtali M. 1999; Fiberless recombinant adenoviruses: virus maturation and infectivity in the absence of fiber. Journal of Virology 73:907–919
     [Google Scholar]
  211. Leon R. P., Hedlund T., Meech S. J., Li S., Schaack J., Hunger S. P., Duke R. C., DeGregori J. 1998; Adenoviral-mediated gene transfer in lymphocytes. Proceedings of the National Academy of Sciences, USA 95:13159–13164
     [Google Scholar]
  212. Leonard G. T., Sen G. C. 1996; Effects of adenovirus E1A protein on interferon-signaling. Virology 224:25–33
     [Google Scholar]
  213. Leonard G. T., Sen G. C. 1997; Restoration of interferon responses of adenovirus E1A-expressing HT1080 cell lines by overexpression of p48 protein. Journal of Virology 71:5095–5101
     [Google Scholar]
  214. Leopold P. L., Kreitzer G., Miyazawa N., Rempel S., Pfister K. K., Rodriguez-Boulan E., Crystal R. G. 2000; Dynein- and microtubule-mediated translocation of adenovirus serotype 5 occurs after endosomal lysis. Human Gene Therapy 11:151–165
     [Google Scholar]
  215. Leppard K. N. 1997; E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections. Journal of General Virology 78:2131–2138
     [Google Scholar]
  216. Leppard K. N., Everett R. D. 1999; The adenovirus type 5 E1b 55K and E4 Orf3 proteins associate in infected cells and affect ND10 components. Journal of General Virology 80:997–1008
     [Google Scholar]
  217. Li W., Berencsi K., Basak S., Somasundaram R., Ricciardi R. P., Gonczol E., Zaloudik J., Linnenbach A., Maruyama H., Miniou P., Herlyn D. 1997; Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice. Journal of Immunology 159:763–769
     [Google Scholar]
  218. Li E., Stupack D., Bokoch G. M., Nemerow G. R. 1998; Adenovirus endocytosis requires actin cytoskeleton reorganization mediated by Rho family GTPases. Journal of Virology 72:8806–8812
     [Google Scholar]
  219. Li H., Alonso-Vanegas M., Colicos M. A., Jung S. S., Lochmuller H., Sadikot A. F., Snipes G. J., Seth P., Karpati G., Nalbantoglu J. 1999a; Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma. Clinical Cancer Research 5:637–642
     [Google Scholar]
  220. Li Y., Kang J., Friedman J., Tarassishin L., Ye J., Kovalenko A., Wallach D., Horwitz M. S. 1999b; Identification of a cell protein (FIP-3) as a modulator of NF-κB activity and as a target of an adenovirus inhibitor of tumor necrosis factor α-induced apoptosis. Proceedings of the National Academy of Sciences, USA 96:1042–1047
     [Google Scholar]
  221. Li Y., Pong R. C., Bergelson J. M., Hall M. C., Sagalowsky A. I., Tseng C. P., Wang Z., Hsieh J. T. 1999 c; Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Research 59:325–330
     [Google Scholar]
  222. Lieber A., He C. Y., Meuse L., Schowalter D., Kirillova I., Winther B., Kay M. A. 1997; The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. Journal of Virology 71:8798–8807
     [Google Scholar]
  223. Lieber A., He C. Y., Meuse L., Himeda C., Wilson C., Kay M. A. 1998; Inhibition of NF-κB activation in combination with bcl-2 expression allows for persistence of first-generation adenovirus vectors in the mouse liver. Journal of Virology 72:9267–9277
     [Google Scholar]
  224. Lieber A., Steinwaerder D. S., Carlson C. A., Kay M. A. 1999; Integrating adenovirus–adeno-associated virus hybrid vectors devoid of all viral genes. Journal of Virology 73:9314–9324
     [Google Scholar]
  225. Lin J., Chen J., Elenbaas B., Levine A. J. 1994; Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes & Development 8:1235–1246
     [Google Scholar]
  226. Linette G. P., Shankara S., Longerich S., Yang S., Doll R., Nicolette C., Preffer F. I., Roberts B. L., Haluska F. G. 2000; In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma. Journal of Immunology 164:3402–3412
     [Google Scholar]
  227. Lipinski K. S., Fax P., Wilker B., Hennemann H., Brockmann D., Esche H. 1999; Differences in the interactions of oncogenic adenovirus 12 early region 1A and nononcogenic adenovirus 2 early region 1A with the cellular coactivators p300 and CBP. Virology 255:94–105
     [Google Scholar]
  228. Look D. C., Roswit W. T., Frick A. G., Gris-Alevy Y., Dickhaus D. M., Walter M. J., Holtzman M. J. 1998; Direct suppression of Stat1 function during adenoviral infection. Immunity 9:871–880
     [Google Scholar]
  229. Lubberts E., Joosten L. A., van den Bersselaar L., Helsen M. M., Bakker A. C., van Meurs J. B., Graham F. L., Richards C. D., van den Berg W. B. 1999; Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. Journal of Immunology 163:4546–4556
     [Google Scholar]
  230. Lukashok S. A., Horwitz M. S. 1998; New perspectives in adenoviruses. Current Clinical Topics in Infectious Diseases 18:286–305
     [Google Scholar]
  231. Lukashok S. A., Tarassishin L., Li Y., Horwitz M. S. 2000; An adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis complexes with dynein and a small GTPase. Journal of Virology 74:4705–4709
     [Google Scholar]
  232. Lusky M., Christ M., Rittner K., Dieterle A., Dreyer D., Mourot B., Schultz H., Stoeckel F., Pavirani A., Mehtali M. 1998; In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. Journal of Virology 72:2022–2032
     [Google Scholar]
  233. Lusky M., Grave L., Dieterle A., Dreyer D., Christ M., Ziller C., Furstenberger P., Kintz J., Ali Hadji D., Pavirani A., Mehtali M. 1999; Regulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3. Journal of Virology 73:8308–8319
     [Google Scholar]
  234. Lutz P., Kedinger C. 1996; Properties of the adenovirus IVa2 gene product, an effector of late-phase-dependent activation of the major late promoter. Journal of Virology 70:1396–1405
     [Google Scholar]
  235. Lutz P., Rosa-Calatrava M., Kedinger C. 1997; The product of the adenovirus intermediate gene IX is a transcriptional activator. Journal of Virology 71:5102–5109
     [Google Scholar]
  236. McDonald C., Reich N. C. 1999; Cooperation of the transcriptional coactivators CBP and p300 with Stat6. Journal of Interferon and Cytokine Research 19:711–722
     [Google Scholar]
  237. Maestro R., Dei Tos A. P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., Doglioni C., Beach D. H., Hannon G. J. 1999; Twist is a potential oncogene that inhibits apoptosis. Genes & Development 13:2207–2217
     [Google Scholar]
  238. Mahr J. A., Gooding L. R. 1999; Immune evasion by adenoviruses. Immunological Reviews 168:121–130
     [Google Scholar]
  239. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M., Lipsky P. 1999; Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939
     [Google Scholar]
  240. Mannervik M., Fan S., Strom A. C., Helin K., Akusjarvi G. 1999; Adenovirus E4 open reading frame 4-induced dephosphorylation inhibits E1A activation of the E2 promoter and E2F-1-mediated transactivation independently of the retinoblastoma tumor suppressor protein. Virology 256:313–321
     [Google Scholar]
  241. Manome Y., Abe M., Hagen M. F., Fine H. A., Kufe D. W. 1994; Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Research 54:5408–5413
     [Google Scholar]
  242. Marshall E. 1999; Gene therapy death prompts review of adenovirus vector. Science 286:2244–2245
     [Google Scholar]
  243. Martin-Duque P., Sanchez-Prieto R., Romero J., Martinez-Lamparero A., Cebrian-Sagarriga S., Guinea-Viniegra J., Dominguez C., Lleonart M., Cano A., Quintanilla M., Ramon Y. C. S. 1999; In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors. International Journal of Oncology 15:1163–1168
     [Google Scholar]
  244. Massie B., Couture F., Lamoureux L., Mosser D. D., Guilbault C., Jolicoeur P., Belanger F., Langelier Y. 1998; Inducible overexpression of a toxic protein by an adenovirus vector with a tetracycline-regulatable expression cassette. Journal of Virology 72:2289–2296
     [Google Scholar]
  245. Mathews M. B., Shenk T. 1991; Adenovirus-associated RNA and translational control. Journal of Virology 65:5657–5662
     [Google Scholar]
  246. Mathias P., Galleno M., Nemerow G. R. 1998; Interactions of soluble recombinant integrin αv β5 with human adenoviruses. Journal of Virology 72:8669–8675
     [Google Scholar]
  247. Matthews D. A., Russell W. C. 1994; Adenovirus protein–protein interactions: hexon and protein VI. Journal of General Virology 75:3365–3374
     [Google Scholar]
  248. Matthews D. A., Russell W. C. 1995; Adenovirus protein–protein interactions: molecular parameters governing the binding of protein VI to hexon and the activation of the adenovirus 23K protease. Journal of General Virology 76:1959–1969
     [Google Scholar]
  249. Matthews D. A., Russell W. C. 1998a; Adenovirus core protein V is delivered by the invading virus to the nucleus of the infected cell and later in infection is associated with nucleoli. Journal of General Virology 79:1671–1675
     [Google Scholar]
  250. Matthews D. A., Russell W. C. 1998b; Adenovirus core protein V interacts with p32 – a protein which is associated with both the mitochondria and the nucleus. Journal of General Virology 79:1677–1685
     [Google Scholar]
  251. Matthews D. A., Cummings D., Evelegh C., Graham F. L., Prevec L. 1999; Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. Journal of General Virology 80:345–353
     [Google Scholar]
  252. Mautner V. 1989; Adenoviridae . In. Andrewes’ Viruses of Vertebrates pp 249–282 Edited by Porterfield J. S. London: Ballière Tindall;
     [Google Scholar]
  253. Mazzarelli J. M., Mengus G., Davidson I., Ricciardi R. P. 1997; The transactivation domain of adenovirus E1A interacts with the C terminus of human TAFII135. Journal of Virology 71:7978–7983
     [Google Scholar]
  254. Mazzolini G., Qian C., Narvaiza I., Barajas M., Borras-Cuesta F., Xie X., Duarte M., Melero I., Prieto J. 2000; Adenoviral gene transfer of interleukin 12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Human Gene Therapy 11:113–125
     [Google Scholar]
  255. Meloni A. R., Smith E. J., Nevins J. R. 1999; A mechanism for Rb/p130-mediated transcription repression involving recruitment of the CtBP corepressor. Proceedings of the National Academy of Sciences, USA 96:9574–9579
     [Google Scholar]
  256. Mentel R., Dopping G., Wegner U., Seidel W., Liebermann H., Dohner L. 1997; Adenovirus-receptor interaction with human lymphocytes. Journal of Medical Virology 51:252–257
     [Google Scholar]
  257. Meredith J. E. Jr, Winitz S., Lewis J. M., Hess S., Ren X. D., Renshaw M. W., Schwartz M. A. 1996; The regulation of growth and intracellular signaling by integrins. Endocrinology Reviews 17:207–220
     [Google Scholar]
  258. Mette S. A., Pilewski J., Buck C. A., Albelda S. M. 1993; Distribution of integrin cell adhesion receptors on normal bronchial epithelial cells and lung cancer cells in vitro and in vivo. American Journal of Research in Respiratory Cell and Molecular Biology 8:562–572
     [Google Scholar]
  259. Michael S. I., Hong J. S., Curiel D. T., Engler J. A. 1995; Addition of a short peptide ligand to the adenovirus fiber protein. Gene Therapy 2:660–668
     [Google Scholar]
  260. Michou A. I., Lehrmann H., Saltik M., Cotten M. 1999; Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors. Journal of Virology 73:1399–1410
     [Google Scholar]
  261. Millecamps S., Kiefer H., Navarro V., Geoffroy M. C., Robert J. J., Finiels F., Mallet J., Barkats M. 1999; Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression. Nature Biotechnology 17:865–869
     [Google Scholar]
  262. Miller N., Whelan J. 1997; Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Human Gene Therapy 8:803–815
     [Google Scholar]
  263. Miller C. R., Buchsbaum D. J., Reynolds P. N., Douglas J. T., Gillespie G. Y., Mayo M. S., Raben D., Curiel D. T. 1998; Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Research 58:5738–5748
     [Google Scholar]
  264. Miyazawa N., Leopold P. L., Hackett N. R., Ferris B., Worgall S., Falck-Pedersen E., Crystal R. G. 1999; Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. Journal of Virology 73:6056–6065
     [Google Scholar]
  265. Mizuguchi H., Kay M. A. 1998; Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Human Gene Therapy 9:2577–2583
     [Google Scholar]
  266. Moorhead J. W., Clayton G. H., Smith R. L., Schaack J. 1999; A replication-incompetent adenovirus vector with the preterminal protein gene deleted efficiently transduces mouse ears. Journal of Virology 73:1046–1053
     [Google Scholar]
  267. Morral N., O’Neal W., Rice K., Leland M., Kaplan J., Piedra P. A., Zhou H., Parks R. J., Velji R., Aguilar-Cordova E., Wadsworth S., Graham F. L., Kochanek S., Carey K. D., Beaudet A. L. 1999; Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proceedings of the National Academy of Sciences, USA 96:12816–12821
     [Google Scholar]
  268. Morsy M. A., Gu M., Motzel S., Zhao J., Lin J., Su Q., Allen H., Franlin L., Parks R. J., Graham F. L., Kochanek S., Bett A. J., Caskey C. T. 1998; An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proceedings of the National Academy of Sciences, USA 95:7866–7871
     [Google Scholar]
  269. Motoi F., Sunamura M., Ding L., Duda D. G., Yoshida Y., Zhang W., Matsuno S., Hamada H. 2000; Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Human Gene Therapy 11:223–235
     [Google Scholar]
  270. Murray K. D., Etheridge C. J., Shah S. I., Matthews D. A., Russell W. C., Miller A. D., Gurling H. M. D. 2000; Synthetic viral vector complexes: enhanced cationic liposome-mediated transfection using the viral DNA-binding protein Mu. Gene Therapy (in press)
    [Google Scholar]
  271. Muruve D. A., Barnes M. J., Stillman I. E., Libermann T. A. 1999; Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Human Gene Therapy 10:965–976
     [Google Scholar]
  272. Ng P., Parks R. J., Cummings D. T., Evelegh C. M., Sankar U., Graham F. L. 1999; A high-efficiency Cre/loxP-based system for construction of adenoviral vectors. Human Gene Therapy 10:2667–2672
     [Google Scholar]
  273. O’Connor M. J., Zimmermann H., Nielsen S., Bernard H. U., Kouzarides T. 1999; Characterization of an E1A–CBP interaction defines a novel transcriptional adapter motif (TRAM) in CBP/p300. Journal of Virology 73:3574–3581
     [Google Scholar]
  274. Ohi N., Tokunaga A., Tsunoda H., Nakano K., Haraguchi K., Oda K., Motoyama N., Nakajima T. 1999; A novel adenovirus E1B19K-binding protein B5 inhibits apoptosis induced by Nip3 by forming a heterodimer through the C-terminal hydrophobic region. Cell Death and Differentiation 6:314–325
     [Google Scholar]
  275. O’Riordan C. R., Lachapelle A., Delgado C., Parkes V., Wadsworth S. C., Smith A. E., Francis G. E. 1999; PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Human Gene Therapy 10:1349–1358
     [Google Scholar]
  276. Ozawa H., Ding W., Torii H., Hosoi J., Seiffert K., Campton K., Hackett N. R., Topf N., Crystal R. G., Granstein R. D. 1999; Granulocyte–macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity. Journal of Investigative Dermatology 113:999–1005
     [Google Scholar]
  277. Pahl H. L., Sester M., Burgert H. G., Baeuerle P. A. 1996; Activation of transcription factor NF-κB by the adenovirus E3/19K protein requires its ER retention. Journal of Cell Biology 132:511–522
     [Google Scholar]
  278. Parks R. J., Graham F. L. 1997; A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. Journal of Virology 71:3293–3298
     [Google Scholar]
  279. Parks R. J., Chen L., Anton M., Sankar U., Rudnicki M. A., Graham F. L. 1996; A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proceedings of the National Academy of Sciences, USA 93:13565–13570
     [Google Scholar]
  280. Parks E., Strieter R. M., Lukacs N. W., Gauldie J., Hitt M., Graham F. L., Kunkel S. L. 1998; Transient gene transfer of IL-12 regulates chemokine expression and disease severity in experimental arthritis. Journal of Immunology 160:4615–4619
     [Google Scholar]
  281. Parks R., Evelegh C., Graham F. 1999a; Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Therapy 6:1565–1573
     [Google Scholar]
  282. Parks R. J., Bramson J. L., Wan Y., Addison C. L., Graham F. L. 1999b; Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors. Journal of Virology 73:8027–8034
     [Google Scholar]
  283. Pastore L., Morral N., Zhou H., Garcia R., Parks R. J., Kochanek S., Graham F. L., Lee B., Beaudet A. L. 1999; Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Human Gene Therapy 10:1773–1781
     [Google Scholar]
  284. Patel S. R., Lee L. Y., Mack C. A., Polce D. R., El-Sawy T., Hackett N. R., Ilercil A., Jones E. C., Hahn R. T., Isom O. W., Rosengart T. K., Crystal R. G. 1999; Safety of direct myocardial administration of an adenovirus vector encoding vascular endothelial growth factor 121. Human Gene Therapy 10:1331–1348
     [Google Scholar]
  285. Paulson M., Pisharody S., Pan L., Guadagno S., Mui A. L., Levy D. E. 1999; Stat protein transactivation domains recruit p300/CBP through widely divergent sequences. Journal of Biological Chemistry 274:25343–25349
     [Google Scholar]
  286. Pearson A. S., Spitz F. R., Swisher S. G., Kataoka M., Sarkiss M. G., Meyn R. E., McDonnell T. J., Cristiano R. J., Roth J. A. 2000; Up-regulation of the proapoptotic mediators Bax and Bak after adenovirus-mediated p53 gene transfer in lung cancer cells. Clinical Cancer Research 6:887–890
     [Google Scholar]
  287. Peng Y., Trevejo J., Zhou J., Marino M. W., Crystal R. G., Falck-Pedersen E., Elkon K. B. 1999; Inhibition of tumor necrosis factor alpha by an adenovirus-encoded soluble fusion protein extends transgene expression in the liver and lung. Journal of Virology 73:5098–5109
     [Google Scholar]
  288. Perissi V., Dasen J. S., Kurokawa R., Wang Z., Korzus E., Rose D. W., Glass C. K., Rosenfeld M. G. 1999; Factor-specific modulation of CREB-binding protein acetyltransferase activity. Proceedings of the National Academy of Sciences, USA 96:3652–3657
     [Google Scholar]
  289. Pickles R. J., McCarty D., Matsui H., Hart P. J., Randell S. H., Boucher R. C. 1998; Limited entry of adenovirus vectors into well-differentiated airway epithelium is responsible for inefficient gene transfer. Journal of Virology 72:6014–6023
     [Google Scholar]
  290. Piedimonte G., Pickles R. J., Lehmann J. R., McCarty D., Costa D. L., Boucher R. C. 1997; Replication-deficient adenoviral vector for gene transfer potentiates airway neurogenic inflammation. American Journal of Research in Respiratory Cell and Molecular Biology 16:250–258
     [Google Scholar]
  291. Poller W., Schneider-Rasp S., Liebert U., Merklein F., Thalheimer P., Haack A., Schwaab R., Schmitt C., Brackmann H. H. 1996; Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Therapy 3:521–530
     [Google Scholar]
  292. Printz M. A., Gonzalez A. M., Cunningham M., Gu D. L., Ong M., Pierce G. F., Aukerman S. L. 2000; Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. Human Gene Therapy 11:191–204
     [Google Scholar]
  293. Prives C., Hall P. A. 1999; The p53 pathway. Journal of Pathology 187:112–126
     [Google Scholar]
  294. Putzer B. M., Bramson J. L., Addison C. L., Hitt M., Siegel P. M., Muller W. J., Graham F. L. 1998; Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Human Gene Therapy 9:707–718
     [Google Scholar]
  295. Putzer B. M., Stiewe T., Parssanedjad K., Rega S., Esche H. 2000; E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products. Cell Death and Differentiation 7:177–188
     [Google Scholar]
  296. Qiu C., De Young M. B., Finn A., Dichek D. A. 1998; Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and αv-integrins. Human Gene Therapy 9:507–520
     [Google Scholar]
  297. Ramalingam R., Rafii S., Worgall S., Hackett N. R., Crystal R. G. 1999; Induction of endogenous genes following infection of human endothelial cells with an E1−E4+ adenovirus gene transfer vector. Journal of Virology 73:10183–10190
     [Google Scholar]
  298. Ramondetta L., Mills G. B., Burke T. W., Wolf J. K. 2000; Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clinical Cancer Research 6:278–284
     [Google Scholar]
  299. Rancourt C., Piche A., Gomez-Navarro J., Wang M., Alvarez R. D., Siegal G. P., Fuller G. M., Jones S. A., Curiel D. T. 1999; Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy. Clinical Cancer Research 5:43–50
     [Google Scholar]
  300. Rao L., Perez D., White E. 1996; Lamin proteolysis facilitates nuclear events during apoptosis. Journal of Cell Biology 135:1441–1455
     [Google Scholar]
  301. Rasmussen U. B., Benchaibi M., Meyer V., Schlesinger Y., Schughart K. 1999; Novel human gene transfer vectors: evaluation of wild-type and recombinant animal adenoviruses in human-derived cells. Human Gene Therapy 10:2587–2599
     [Google Scholar]
  302. Rauma T., Tuukkanen J., Bergelson J. M., Denning G., Hautala T. 1999; rab5 GTPase regulates adenovirus endocytosis. Journal of Virology 73:9664–9668
     [Google Scholar]
  303. Rea D., Schagen F. H., Hoeben R. C., Mehtali M., Havenga M. J., Toes R. E., Melief C. J., Offringa R. 1999; Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. Journal of Virology 73:10245–10253
     [Google Scholar]
  304. Recchia A., Parks R. J., Lamartina S., Toniatti C., Pieroni L., Palombo F., Ciliberto G., Graham F. L., Cortese R., La Monica N., Colloca S. 1999; Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector. Proceedings of the National Academy of Sciences, USA 96:2615–2620
     [Google Scholar]
  305. Reddy P. S., Idamakanti N., Chen Y., Whale T., Babiuk L. A., Mehtali M., Tikoo S. K. 1999; Replication-defective bovine adenovirus type 3 as an expression vector. Journal of Virology 73:9137–9144
     [Google Scholar]
  306. Reich N., Pine R., Levy D., Darnell J. E. Jr 1988; Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products. Journal of Virology 62:114–119
     [Google Scholar]
  307. Reid J. L., Bannister A. J., Zegerman P., Martinez-Balbas M. A., Kouzarides T. 1998; E1A directly binds and regulates the P/CAF acetyltransferase. EMBO Journal 17:4469–4477
     [Google Scholar]
  308. Rekosh D. M., Russell W. C., Bellet A. J., Robinson A. J. 1977; Identification of a protein linked to the ends of adenovirus DNA. Cell 11:283–295
     [Google Scholar]
  309. Ridet J. L., Corti O., Pencalet P., Hanoun N., Hamon M., Philippon J., Mallet J. 1999; Toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes. Human Gene Therapy 10:271–280
     [Google Scholar]
  310. Ridgway P. J., Hall A. R., Myers C. J., Braithwaite A. W. 1997; p53/E1b58kDa complex regulates adenovirus replication. Virology 237:404–413
     [Google Scholar]
  311. Rodriguez R., Schuur E. R., Lim H. Y., Henderson G. A., Simons J. W., Henderson D. R. 1997; Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 57:2559–2563
     [Google Scholar]
  312. Rodriguez M. S., Desterro J. M., Lain S., Midgley C. A., Lane D. P., Hay R. T. 1999; SUMO-1 modification activates the transcriptional response of p53. EMBO Journal 18:6455–6461
     [Google Scholar]
  313. Roelvink P. W., Lizonova A., Lee J. G., Li Y., Bergelson J. M., Finberg R. W., Brough D. E., Kovesdi I., Wickham T. J. 1998; The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. Journal of Virology 72:7909–7915
     [Google Scholar]
  314. Rogers B. E., McLean S. F., Kirkman R. L., Della Manna D., Bright S. J., Olsen C. C., Myracle A. D., Mayo M. S., Curiel D. T., Buchsbaum D. J. 1999; In vivo localization of [111In]-DTPA-d-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clinical Cancer Research 5:383–393
     [Google Scholar]
  315. Rogulski K. R., Wing M. S., Paielli D. L., Gilbert J. D., Kim J. H., Freytag S. O. 2000; Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Human Gene Therapy 11:67–76
     [Google Scholar]
  316. Rosenberg S. A., Zhai Y., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Seipp C. A., Einhorn J. H., Roberts B., White D. E. 1998; Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. Journal of the National Cancer Institute 90:1894–1900
     [Google Scholar]
  317. Rowe W. P., Huebner R. J., Gilmore L. K., Parrot R. H., Ward T. G. 1953; Isolation of a cytopathic agent from human adenoids undergoing spontaneous degradation in tissue culture. Proceedings of the Society for Experimental Biology and Medicine 84:570–573
     [Google Scholar]
  318. Russell W. C., Valentine R. C., Pereira H. G. 1967; The effect of heat on the anatomy of the adenovirus. Journal of General Virology 1:509–522
     [Google Scholar]
  319. Ryan K. M., Ernst M. K., Rice N. R., Vousden K. H. 2000; Role of NF-kappaB in p53-mediated programmed cell death. Nature 404:892–897
     [Google Scholar]
  320. Sallenave J. M., Xing Z., Simpson A. J., Graham F. L., Gauldie J. 1998; Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promoters. Gene Therapy 5:352–360
     [Google Scholar]
  321. Sanchez-Cespedes M., Reed A. L., Buta M., Wu L., Westra W. H., Herman J. G., Yang S. C., Jen J., Sidransky D. 1999; Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 18:5843–5849
     [Google Scholar]
  322. Sandig V., Loser P., Lieber A., Kay M. A., Strauss M. 1996; HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Therapy 3:1002–1009
     [Google Scholar]
  323. Sandy P., Gostissa M., Fogal V., Cecco L. D., Szalay K., Rooney R. J., Schneider C., Del Sal G. 2000; p53 is involved in the p120E4F-mediated growth arrest. Oncogene 19:188–199
     [Google Scholar]
  324. Santis G., Legrand V., Hong S. S., Davison E., Kirby I., Imler J.-L., Finberg R. W., Bergelson J. M., Mehtali M., Boulanger P. 1999; Molecular determinants of adenovirus serotype 5 fibre binding to its cellular receptor CAR. Journal of General Virology 80:1519–1527
     [Google Scholar]
  325. Schmitz M. L., Indorf A., Limbourg F. P., Stadtler H., Traenckner E. B., Baeuerle P. A. 1996; The dual effect of adenovirus type 5 E1A 13S protein on NF-κB activation is antagonized by E1B 19K. Molecular Cell Biology 16:4052–4063
     [Google Scholar]
  326. Schneider D. B., Sassani A. B., Vassalli G., Driscoll R. M., Dichek D. A. 1999; Adventitial delivery minimizes the proinflammatory effects of adenoviral vectors. Journal of Vascular Surgery 29:543–550
     [Google Scholar]
  327. Schowalter D. B., Himeda C. L., Winther B. L., Wilson C. B., Kay M. A. 1999; Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice. Journal of Virology 73:4755–4766
     [Google Scholar]
  328. Segerman A., Mei Y. F., Wadell G. 2000; Adenovirus types 11p and 35p show high binding efficiencies for committed hematopoietic cell lines and are infective to these cell lines. Journal of Virology 74:1457–1467
     [Google Scholar]
  329. Shalev M., Kadmon D., Teh B. S., Butler E. B., Aguilar-Cordova E., Thompson T. C., Herman J. R., Adler H. L., Scardino P. T., Miles B. J. 2000; Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. Journal of Urology 163:1747–1750
     [Google Scholar]
  330. Shao R., Karunagaran D., Zhou B. P., Li K., Lo S. S., Deng J., Chiao P., Hung M. C. 1997; Inhibition of nuclear factor-κB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. Journal of Biological Chemistry 272:32739–32742
     [Google Scholar]
  331. Shao R., Hu M. C., Zhou B. P., Lin S. Y., Chiao P. J., von Lindern R. H., Spohn B., Hung M. C. 1999; E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IκB kinases and nuclear factor κB activities. Journal of Biological Chemistry 274:21495–21498
     [Google Scholar]
  332. Shih I. M., Yu J., He T. C., Vogelstein B., Kinzler K. W. 2000; The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression. Cancer Research 60:1671–1676
     [Google Scholar]
  333. Shinoura N., Muramatsu Y., Yoshida Y., Asai A., Kirino T., Hamada H. 2000; Adenovirus-mediated transfer of caspase-3 with Fas ligand induces drastic apoptosis in U-373MG glioma cells. Experimental Cell Research 256:423–433
     [Google Scholar]
  334. Shisler J., Duerksen-Hughes P., Hermiston T. M., Wold W. S., Gooding L. R. 1996; Induction of susceptibility to tumor necrosis factor by E1A is dependent on binding to either p300 or p105-Rb and induction of DNA synthesis. Journal of Virology 70:68–77
     [Google Scholar]
  335. Siders W. M., Halloran P. J., Fenton R. G. 1998a; Melanoma-specific cytotoxicity induced by a tyrosinase promoter–enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Therapy 5:281–291
     [Google Scholar]
  336. Siders W. M., Wright P. W., Hixon J. A., Alvord W. G., Back T. C., Wiltrout R. H., Fenton R. G. 1998b; T cell- and NK cell-independent inhibition of hepatic metastases by systemic administration of an IL-12-expressing recombinant adenovirus. Journal of Immunology 160:5465–5474
     [Google Scholar]
  337. Simos G., Georgatos S. D. 1994; The lamin B receptor-associated protein p34 shares sequence homology and antigenic determinants with the splicing factor 2-associated protein p32. FEBS Letters 346:225–228
     [Google Scholar]
  338. Smith T. A., White B. D., Gardner J. M., Kaleko M., McClelland A. 1996; Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Therapy 3:496–502
     [Google Scholar]
  339. Smith C. A., Woodruff L. S., Rooney C., Kitchingman G. R. 1998; Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Human Gene Therapy 9:1419–1427
     [Google Scholar]
  340. Somasundaram K., El-Deiry W. S. 1997; Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 14:1047–1057
     [Google Scholar]
  341. Souberbielle B. E., Russell W. C. 1995; Human T cell proliferative response to polypeptides from adenovirus type 2. Journal of Infectious Diseases 172:1421–1422
     [Google Scholar]
  342. Staba M. J., Wickham T. J., Kovesdi I., Hallahan D. E. 2000; Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Therapy 7:13–19
     [Google Scholar]
  343. Steiner M. S., Zhang Y., Farooq F., Lerner J., Wang Y., Lu Y. 2000; Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Therapy 7:360–372
     [Google Scholar]
  344. Steinwaerder D. S., Carlson C. A., Lieber A. 1999; Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats. Journal of Virology 73:9303–9313
     [Google Scholar]
  345. Sterman D. H., Treat J., Litzky L. A., Amin K. M., Coonrod L., Molnar-Kimber K., Recio A., Knox L., Wilson J. M., Albelda S. M., Kaiser L. R. 1998; Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Human Gene Therapy 9:1083–1092
     [Google Scholar]
  346. Stevenson S. C., Rollence M., White B., Weaver L., McClelland A. 1995; Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. Journal of Virology 69:2850–2857
     [Google Scholar]
  347. Stewart P. L., Fuller S. D., Burnett R. M. 1993; Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO Journal 12:2589–2599
     [Google Scholar]
  348. Stewart P. L., Chiu C. Y., Huang S., Muir T., Zhao Y., Chait B., Mathias P., Nemerow G. R. 1997; Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. EMBO Journal 16:1189–1198
     [Google Scholar]
  349. Suomalainen M., Nakano M. Y., Keller S., Boucke K., Stidwill R. P., Greber U. F. 1999; Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus. Journal of Cell Biology 144:657–672
     [Google Scholar]
  350. Suzuki T., Anderegg B., Ohkawa T., Irie A., Engebraaten O., Halks-Miller M., Holm P. S., Curiel D. T., Kashani-Sabet M., Scanlon K. J. 2000; Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits in vivo growth of breast cancer cells. Gene Therapy 7:241–248
     [Google Scholar]
  351. Tan B. T., Wu L., Berk A. J. 1999; An adenovirus–Epstein–Barr virus hybrid vector that stably transforms cultured cells with high efficiency. Journal of Virology 73:7582–7589
     [Google Scholar]
  352. Tanaka N., Sato M., Lamphier M. S., Nozawa H., Oda E., Noguchi S., Schreiber R. D., Tsujimoto Y., Taniguchi T. 1998; Type I interferons are essential mediators of apoptotic death in virally infected cells. Genes and Cells 3:29–37
     [Google Scholar]
  353. Taniguchi T., Chikatsu N., Takahashi S., Fujita A., Uchimaru K., Asano S., Fujita T., Motokura T. 1999; Expression of p16INK4A and p14ARF in hematological malignancies. Leukemia 13:1760–1769
     [Google Scholar]
  354. Tao W., Levine A. J. 1999; P19 (ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proceedings of the National Academy of Sciences USA: 96:6937–6941
     [Google Scholar]
  355. Tashiro F., Niwa H., Miyazaki J. 1999; Constructing adenoviral vectors by using the circular form of the adenoviral genome cloned in a cosmid and the Cre-loxP recombination system. Human Gene Therapy 10:1845–1852
     [Google Scholar]
  356. Tillman B. W., de Gruijl T. D., Luykx-de Bakker S. A., Scheper R. J., Pinedo H. M., Curiel T. J., Gerritsen W. R., Curiel D. T. 1999; Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. Journal of Immunology 162:6378–6383
     [Google Scholar]
  357. Tollefson A. E., Ryerse J. S., Scaria A., Hermiston T. W., Wold W. S. 1996; The E3-11·6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220:152–162
     [Google Scholar]
  358. Tollefson A. E., Hermiston T. W., Lichtenstein D. L., Colle C. F., Tripp R. A., Dimitrov T., Toth K., Wells C. E., Doherty P. C., Wold W. S. 1998; Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392:726–730
     [Google Scholar]
  359. Toloza E. M., Hunt K., Swisher S., McBride W., Lau R., Pang S., Rhoades K., Drake T., Belldegrun A., Glaspy J., Economou J. S. 1996; In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Therapy 3:11–17
     [Google Scholar]
  360. Tomko R. P., Xu R., Philipson L. 1997; HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proceedings of the National Academy of Sciences USA: 94:3352–3356
     [Google Scholar]
  361. Tomko R. P., Johansson C. B., Totrov M., Abagyan R., Frisen J., Philipson L. 2000; Expression of the adenovirus receptor and its interaction with the fiber knob. Experimental Cell Research 255:47–55
     [Google Scholar]
  362. Topf N., Worgall S., Hackett N. R., Crystal R. G. 1998; Regional ‘pro-drug’ gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma. Gene Therapy 5:507–513
     [Google Scholar]
  363. Tsao Y. P., Huang S. J., Chang J. L., Hsieh J. T., Pong R. C., Chen S. L. 1999; Adenovirus-mediated p21WAF1/SDII/CIP1 gene transfer induces apoptosis of human cervical cancer cell lines. Journal of Virology 73:4983–4990
     [Google Scholar]
  364. Tuting T., Steitz J., Bruck J., Gambotto A., Steinbrink K., DeLeo A. B., Robbins P., Knop J., Enk A. H. 1999; Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective anti-melanoma immunity. Journal of Genetic Medicine 1:400–406
     [Google Scholar]
  365. van Deutekom J. C., Cao B., Pruchnic R., Wickham T. J., Kovesdi I., Huard J. 1999; Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle. Journal of Genetic Medicine 1:393–399
     [Google Scholar]
  366. van Ginkel F. W., McGhee J. R., Liu C., Simecka J. W., Yamamoto M., Frizzell R. A., Sorscher E. J., Kiyono H., Pascual D. W. 1997; Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. Journal of Immunology 159:685–693
     [Google Scholar]
  367. Vollmer C. M., Ribas A., Butterfield L. H., Dissette V. B., Andrews K. J., Eilber F. C., Montejo L. D., Chen A. Y., Hu B., Glaspy J. A., McBride W. H., Economou J. S. 1999; p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Research 59:4369–4374
     [Google Scholar]
  368. von Herrath M. G., Efrat S., Oldstone M. B., Horwitz M. S. 1997; Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes. Proceedings of the National Academy of Sciences USA: 94:9808–9813
     [Google Scholar]
  369. Von Seggern D. J., Chiu C. Y., Fleck S. K., Stewart P. L., Nemerow G. R. 1999; A helper-independent adenovirus vector with E1, E3, and fiber deleted: structure and infectivity of fiberless particles. Journal of Virology 73:1601–1608
     [Google Scholar]
  370. Walters R. W., Grunst T., Bergelson J. M., Finberg R. W., Welsh M. J., Zabner J. 1999; Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. Journal of Biological Chemistry 274:10219–10226
     [Google Scholar]
  371. Wan Y., Emtage P., Foley R., Carter R., Gauldie J. 1999; Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. International Journal of Oncology 14:771–776
     [Google Scholar]
  372. Wang X., Bergelson J. M. 1999; Coxsackievirus and adenovirus receptor cytoplasmic and transmembrane domains are not essential for coxsackievirus and adenovirus infection. Journal of Virology 73:2559–2562
     [Google Scholar]
  373. Wang K., Huang S., Kapoor-Munshi A., Nemerow G. 1998; Adenovirus internalization and infection require dynamin. Journal of Virology 72:3455–3458
     [Google Scholar]
  374. Watson G., Burdon M. G., Russell W. C. 1988; An antigenic analysis of the adenovirus type 2 fibre polypeptide. Journal of General Virology 69:525–535
     [Google Scholar]
  375. Weber J. 1976; Genetic analysis of adenovirus type 2. III. Temperature sensitivity of processing viral proteins. Journal of Virology 17:462–471
     [Google Scholar]
  376. Weber J. D., Taylor L. J., Roussel M. F., Sherr C. J., Bar-Sagi D. 1999; Nucleolar Arf sequesters Mdm2 and activates p53. Nature Cell Biology 1:20–26
     [Google Scholar]
  377. Webster A., Russell S., Talbot P., Russell W. C., Kemp G. D. 1989; Characterization of the adenovirus proteinase: substrate specificity. Journal of General Virology 70:3225–3234
     [Google Scholar]
  378. Weiden M. D., Ginsberg H. S. 1994; Deletion of the E4 region of the genome produces adenovirus DNA concatemers. Proceedings of the National Academy of Sciences, USA 91:153–157
     [Google Scholar]
  379. Weigel S., Dobbelstein M. 2000; The nuclear export signal within the E4orf6 protein of adenovirus type 5 supports virus replication and cytoplasmic accumulation of viral mRNA. Journal of Virology 74:764–772
     [Google Scholar]
  380. Wickham T. J., Mathias P., Cheresh D. A., Nemerow G. R. 1993; Integrins αv β3 and αv β5 promote adenovirus internalization but not virus attachment. Cell 73:309–319
     [Google Scholar]
  381. Wickham T. J., Roelvink P. W., Brough D. E., Kovesdi I. 1996; Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nature Biotechnology 14:1570–1573
     [Google Scholar]
  382. Wickham T. J., Lee G. M., Titus J. A., Sconocchia G., Bakacs T., Kovesdi I., Segal D. M. 1997; Targeted adenovirus-mediated gene delivery to T cells via CD3. Journal of Virology 71:7663–7669
     [Google Scholar]
  383. Wildner O., Morris J. C., Vahanian N. N., Ford H. Jr, Ramsey W. J., Blaese R. M. 1999; Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Therapy 6:57–62
     [Google Scholar]
  384. Willcox N., Mautner V. 1976; Antigenic determinants of adenovirus capsids. I. Measurement of antibody cross-reactivity. Journal of Immunology 116:19–24
     [Google Scholar]
  385. Wills K. N., Maneval D. C., Menzel P., Harris M. P., Sutjipto S., Vaillancourt M.-T., Huang W.-M., Johnson D. E., Anderson S. C., Wen S. F., Bookstein R., Shepard H. M., Gregory R. J. 1994; Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Human Gene Therapy 5:1079–1088
     [Google Scholar]
  386. Wold W. M., Chinnadurai G. 2000; Adenovirus proteins that regulate apoptosis. In DNA Virus Replication. pp 200–232 Edited by Cann A. J. Oxford: Oxford University Press;
  387. Wolf L. A., Laster S. M. 1999; Characterization of arachidonic acid-induced apoptosis. Cell Biochemistry and Biophysics 30:353–368
     [Google Scholar]
  388. Worgall S., Wolff G., Falck-Pedersen E., Crystal R. G. 1997a; Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Human Gene Therapy 8:37–44
     [Google Scholar]
  389. Worgall S., Leopold P. L., Wolff G., Ferris B., Van Roijen N., Crystal R. G. 1997b; Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Human Gene Therapy 8:1675–1684
     [Google Scholar]
  390. Worgall S., Singh R., Leopold P. L., Kaner R. J., Hackett N. R., Topf N., Moore M. A., Crystal R. G. 1999; Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA. Blood 93:655–666
     [Google Scholar]
  391. Yang L., Lochmuller H., Luo J., Massie B., Nalbantoglu J., Karpati G., Petrof B. J. 1998; Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. Gene Therapy 5:369–379
     [Google Scholar]
  392. Yarosh O. K., Wandeler A. I., Graham F. L., Campbell J. B., Prevec L. 1996; Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 14:1257–1264
     [Google Scholar]
  393. Ye J., Xie X., Tarassishin L., Horwitz M. S. 2000; Regulation of the NF-κB activation pathway by isolated domains of FIP3/IKKγ, a component of the IκB-α kinase complex. Journal of Biological Chemistry 275:9882–9889
     [Google Scholar]
  394. Yew N. S., Marshall J., Przybylska M., Wysokenski D. M., Ziegler R. J., Rafter P. W., Li C., Armentano D., Cheng S. H. 1999; Increased duration of transgene expression in the lung with plasmid DNA vectors harboring adenovirus E4 open reading frame 3. Human Gene Therapy 10:1833–1843
     [Google Scholar]
  395. Yu D. C., Chen Y., Seng M., Dilley J., Henderson D. R. 1999; The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Research 59:4200–4203
     [Google Scholar]
  396. Yuasa K., Miyagoe Y., Yamamoto K., Nabeshima Y., Dickson G., Takeda S. 1998; Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Letters 425:329–336
     [Google Scholar]
  397. Yun J., Chae H. D., Choy H. E., Chung J., Yoo H. S., Han M. H., Shin D. Y. 1999; p53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. Journal of Biological Chemistry 274:29677–29682
     [Google Scholar]
  398. Zabner J., Freimuth P., Puga A., Fabrega A., Welsh M. J. 1997; Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. Journal of Clinical Investigation 100:1144–1149
     [Google Scholar]
  399. Zabner J., Chillon M., Grunst T., Moninger T. O., Davidson B. L., Gregory R., Armentano D. 1999; A chimeric type 2 adenovirus vector with a type 17 fiber enhances gene transfer to human airway epithelia. Journal of Virology 73:8689–8695
     [Google Scholar]
  400. Zakhartchouk A. N., Reddy P. S., Baxi M., Baca-Estrada M. E., Mehtali M., Babiuk L. A., Tikoo S. K. 1998; Construction and characterization of E3-deleted bovine adenovirus type 3 expressing full-length and truncated form of bovine herpesvirus type 1 glycoprotein gD. Virology 250:220–229
     [Google Scholar]
  401. Zantema A., van der Eb A. 2000; Control of transcription by adenovirus-E1A proteins. In DNA Virus Replication pp 173–199 Edited by Cann A. J. Oxford: Oxford University Press;
     [Google Scholar]
  402. Zhang W.-W. 1999; Development and application of adenoviral vectors for gene therapy of cancer. Cancer Gene Therapy 6:113–138
     [Google Scholar]
  403. Zhang R., DeGroot L. J. 2000; Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: relationship of bystander effect and antitumor efficacy. Thyroid 10:313–319
     [Google Scholar]
  404. Zhang F., Andreassen P., Fender P., Geissler E., Hernandez J. F., Chroboczek J. 1999; A transfecting peptide derived from adenovirus fiber protein. Gene Therapy 6:171–181
     [Google Scholar]
  405. Zheng C., Baum B. J., Iadarola M. J., O’Connell B. C. 2000; Genomic integration and gene expression by a modified adenoviral vector. Nature Biotechnology 18:176–180
     [Google Scholar]
  406. Zhong L., Granelli-Piperno A., Choi Y., Steinman R. M. 1999; Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. European Journal of Immunology 29:964–972
     [Google Scholar]
  407. Zuckerman J. B., Robinson C. B., McCoy K. S., Shell R., Sferra T. J., Chirmule N., Magosin S. A., Propert K. J., Brown-Parr E. C., Hughes J. V., Tazelaar J., Baker C., Goldman M. J., Wilson J. M. 1999; A phase I study of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator gene to a lung segment of individuals with cystic fibrosis. Human Gene Therapy 10:2973–2985
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-81-11-2573
Loading
Update on adenovirus and its vectors
J. Gen. Virol. 81, 2573 (2000); https://doi.org/10.1099/0022-1317-81-11-2573
/content/journal/jgv/10.1099/0022-1317-81-11-2573
/content/journal/jgv/10.1099/0022-1317-81-11-2573
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error